CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Oncology in vitro services

Explore drug pharmacokinetics, scheduling, and combinations without xenografts


Our unique Oncology in vitro Service combines innovative technology with deep cell culture expertise to enable a first–exploration of the pharmacokinetic/pharmacodynamic (PK/PD) and efficacy relationship in vitro.

Use this service to validate and explore in vivo or in silico findings and perform experiments that wouldn’t be possible otherwise.

Service overview:

  • Compare in vitro cell and tumor model responses to murine and human PK profiles
  • Explore the effects of drug combination therapies and dosing schedules
  • Evaluate in silico predictions
  • Define PK/PD relationships to guide xenograft or clinical study design
  • Investigate the human relevance of xenograft results 

How the service works:

  1. Our specialist team works with you to formulate an experimental design
  2. You submit your test agent and in vitro model for culture in 2D or 3D.
  3. We apply varying concentrations of one or two drugs in combination that accurately recreate in vivo or in silico PK profiles
  4. PK profiles are repeated every 12, 24, or 48 hours
  5. Full report with option to receive cell and media samples for molecular mechanism investigation

Related applications

Oncology


Oncology services photo

Learn more about our Oncology Services

Request more info

Featured resources

Webinars

web s3e4 |

Bringing Life to PK Profiles: In Vivo-Relevance From an In Vitro Environment.

Scientific publications

PLOS 2022 DS PK Graphic |

A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models

Posters

In vitro assessment of combination dosing regimens with in vivo like PK EDIT |

In vitro assessment of combination dosing regimen with in vivo-like pharmacokinetic concentration profiles enabled by a microfluidic addition and removal device

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023